Efficacy and Safety of Almonertinib Combined With or Without Chemotherapy as an Adjuvant Treatment for Stage II-IIIA Non-small Cell Lung Carcinoma Following Complete Tumour Resection (APEX)
研究单位：[1]Cancer Institute and Hospital,Chinese Academy of Medical Sciences[2]Cancer Hospital Chinese Academy of Medical Sciences Beijing,China[3]Peking Union Medical College Hospital Beijing,China[4]Hunan Cancer Hospital Changsha,China[5]Sichuan Cancer Hospital Chendu,China[6]Sichuan Provincial People's Hospital Chengdu,China[7]The First Affiliated Hospital of Chongqing Medical University Chongqing,China[8]Fujian Medical University Consonancy Hospital Fuzhou,China[9]Guangdong Provincial People's Hospital Guangzhou,China[10]The Second Affiliated Hospital of Zhejiang University School Of Medicine Hangzhou,China[11]The First People's Hospital of Yunnan Province Kunming,China[12]Yunnan Cancer Hospital Kunming,China[13]JiangXi Cancer Hospital Nanchang,China[14]The First Affiliated Hospital of Nanchang University Nanchang,China[15]Jiangsu Cancer Hospital Nanjing,China[16]Jiangsu Provincial People's Hospital Nanjing,China[17]Ningbo Medical Center Li Huili Hospital Ningbo,China[18]Qingdao Municipal Hospital Qingdao,China[19]Fudan University Shanghai Cancer Center Shanghai,China[20]ShangHai Chest Hospital ShangHai JiaoTong University Shanghai,China[21]ShangHai Pulmonary Hospital Shanghai,China[22]Liaoning Cancer Hospital Shenyang,China[23]Cancer Hospital Chinese Academy of Medical Sciences,Shenzhen Center Shenzhen,China[24]Hebei Cancer Hospital Shijiazhuang,China[25]West China Hospital,Sichuan University Sichuan,China[26]The First Affiliated Hospital of Soochow University Suzhou,China[27]Thoracic Surgery Department Of The ShanXi Provincial Cancer Hospital Taiyuan,China[28]Tianjin Chest Hospital Tianjin,China[29]Weifang People's Hospital Weifang,China[30]The First Affiliated Hospital of Wenzhou Medical University Wenzhou,China[31]Wuhan Union Hospital Of China Wuhan,China[32]First Affiliated Hospital of Xi'an Jiaotong University Xi'an,China[33]The First Affiliated Hospital of Zhengzhou University Zhengzhou,China[34]Affiliated Tumor Hospital of Xinjiang Medical University Ürümqi,China
研究目的：
This is a multicenter, randomized, open label, phase III study.
